However, an expanded population (≥10%) of CD34-positive cells lacking common lineage markers and non-CHIP mutations [16] would warrant close observation and potentially early intervention with immunomodulatory therapies that disrupt the MM bone marrow niche. The gene discussed is CD34; the disease is Miyoshi myopathy.